UPDATE: B.Riley Starts Entera Bio (ENTX) at Buy

(Updated - June 16, 2021 7:26 AM EDT)

B.Riley analyst Kalpit Patel initiates coverage on Entera Bio (NASDAQ: ENTX) with a Buy rating and a price target of $9.00.

The analyst comments "We are initiating coverage of Entera Bio Ltd. (ENTX) with a Buy rating and a 12-month price target of $9 per share based on our view that its lead program could achieve a streamlined regulatory path as a first oral osteoanabolic agent for treating osteoporosis. Entera is advancing its proprietary drug formulation technology—which we believe will allow commercialization of other compounds—to enable oral delivery of protein-based therapeutics that are currently only available as injectables. The company’s oral vehicle technology dually incorporates special absorption enhancers and protease inhibitors in an effort to improve bioavailability and limit degradation of the proteins or peptides in the gastrointestinal tract. Entera’s two pipeline candidates, EB613 and EB612, are orally formulated versions of human parathyroid hormone (1-34), or PTH, which are being developed for osteoporosis and hypoparathyroidism, respectively. At an ~$70M enterprise value, we believe ENTX shares offer a reasonably attractive entry point ahead of potentially de-risking final data analyses from an ongoing osteoporosis study in 2Q21."

For an analyst ratings summary and ratings history on Entera Bio click here. For more ratings news on Entera Bio click here.

Shares of Entera Bio closed at $3.73 yesterday.

You May Also Be Interested In

• Jones Trading Starts Ellington (EFC) at Hold
• Boston Beer Company (SAM) PT Lowered to $310 at Evercore ISI
• Hertz Global (HTZ) PT Lowered to $6 at Deutsche Bank